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Objective To explore the psychosocial implications of diagnostic uncertainty that result from inconclusive results
generated by newborn bloodspot screening (NBS) for cystic fibrosis (CF).
Study design Using a mixed methods prospective cohort study of children who received NBS for CF, we com-
pared psychosocial outcomes of parents whose children who received persistently inconclusive results with those
whose children received true positive or screen-negative results.
Results Mothers of infants who received inconclusive results (n = 17), diagnoses of CF (n = 15), and screen-
negative results (n = 411) were surveyed; 23 parent interviews were completed. Compared with mothers of infants
with true positive/screen-negative results, mothers of infants with inconclusive results reported greater perceived
uncertainty (P < .006) but no differences in anxiety or vulnerability (P > .05). Qualitatively, parents valued being con-
nected to experts but struggled with the meaning of an uncertain diagnosis, worried about their infant’s health-
related vulnerability, and had mixed views about surveillance.
Conclusion Inconclusive CF NBS results were not associated with anxiety or vulnerability but led to health-
related uncertainty and qualitative concerns. Findings should be considered alongside efforts to optimize proto-
cols for CF screening and surveillance. Educational and psychosocial supports are warranted for these families. (J
Pediatr 2017;184:165-71).
Although the US Centers for Disease Control hails newborn screening (NBS) as one of the 10 great public health achieve-ments of the last decade,1,2 increasingly sensitive NBS technology leads to the detection of a wider variety of test results(ie, false positive and inconclusive results) with complex effects, increasing the need for research to ensure the public
health benefits of screening are maintained.3-6 We focus herein on the specific challenge of inconclusive results after diagnostic
follow-up testing. For families of infants with such results, there is no clarity on
whether a disease state exists and whether/how to manage it; uncertainty for parents
and health care providers can persist for months or even years.7-21 As NBS panels
continue to expand, evidence to identify the scope of parent-reported outcomes
in the context of diagnostic uncertainty is timely.6
NBS for cystic fibrosis (CF) exemplifies the challenge of inconclusive results.9-15
Although diagnostic uncertainty is not a new phenomenon for individuals with
symptoms of CF,10 NBS- related uncertainty is more complicated because most
newborns are asymptomatic. Moreover, inconclusive CF diagnoses are quite fre-
quent; in the first 6 years of NBS for CF in Ontario, Canada (population 13 million),
150 infants were identified with CF, whereas 68 received inconclusive results.12 Ooi
et al16 recently reported 3-year clinical outcomes of 82 children with inconclu-
sive results and 80 children with CF; CF ultimately was diagnosed in 9 of 82 (11%).
Despite emerging evidence, practice varies with respect to CF screening algo-
rithms, how to refer to this situation (eg, “CFTR-related metabolic syndrome,”“CF
screen positive, inconclusive diagnosis”), and optimal clinical surveillance.12-19
Given this context, the psychosocial impact of this experience warrants
attention. The small number of related studies has yielded equivocal results. An
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ethnography of the families of 24 infants with uncertain
metabolic disease results suggests that families assume the
role of “patients-in-waiting”20; parents perceive their chil-
dren to be neither healthy nor sick for protracted periods of
time, potentially influencing the identity parents attribute to
their child. Although a CF-related, survey-based study did
not detect clinical levels of anxiety among parents of chil-
dren with uncertain CF diagnoses (P > .05), when asked
whether their child’s health status caused them any emo-
tional disturbances, significantly more parents of children
with an uncertain diagnosis endorsed this concern than
parents of healthy children (P = .0003).21 In a qualitative
interview study with 10 parents of 5 infants with inconclu-
sive CF NBS results, Tluczek et al22 identified ongoing
worry and feelings of isolation from the CF community;
however, this negative affect became less pronounced over
time.22
Although qualitative and quantitative indicators of subtle
distress have been reported, constructs specific to the experi-
ence of uncertainty in NBS have not been explored with
validated psychometric tools. Perception of child vulnerabil-
ity, for example, has been reported as a potential indicator of
distress related to infant screening23-25 but has not yet been
applied to inconclusive NBS diagnoses. Unsurprisingly, the
construct of uncertainty also has been identified as central to
the experience of receiving inconclusive NBS CF results22 but
has not been explored with validated tools. We report on
parental psychosocial impact and lived experiences of diag-
nostic uncertainty in collaboration with the International
CF Consortium’s efforts to generate prospective clinical
outcome data to inform screening and follow-up protocols
for these patients.16
Methods
In Ontario, CF NBS involves a 2-step process of measuring
immunoreactive trypsinogen (IRT) followed by screening
the cystic fibrosis transmembrane regulator (CFTR) gene for
39 mutations.16 Confirmatory sweat chloride testing is then
performed on screen-positive infants who are classified sub-
sequently as true positive (ie, 2 CF causing mutations OR
sweat chloride ≥ 60 mmol/L), false positive (ie, 1 CF causing
mutation OR IRT > 99.9th percentile PLUS sweat chloride
concentration <30 mmol/L), or inconclusive (ie, 1 CFTR
mutation OR IRT > 99.9th percentile PLUS sweat chloride
30-59 mmol/L OR sweat chloride concentration <30 mmol/
L + >1 CFTR mutations of uncertain significance). Inconclusive
cases are offered ongoing clinical and/or research follow-up.
This includes optional monitoring and assessment every 6
months following confirmatory testing until 2 years of age
and then annually. Sweat testing, microbiology testing, and
clinical assessment of respiratory and gastrointestinal symp-
toms are included in each assessment. Parents choose to opt
into/out of any of these assessments and can opt into/out of
including their child’s assessment data in the research
database.
Sample
For the component of the study reported herein, the full popu-
lation of mothers of infants with true positive and inconclu-
sive results seen at The Hospital for Sick Children in Toronto
and a screen negative control sample were invited to partici-
pate during an 18-month period, via a modified Dillman
design.26,27 Because of the small number of inconclusive cases,
we broadened the inclusion age, recruiting mothers retrospec-
tively whose infants remained inconclusive with respect to di-
agnosis and were between the ages of 4 and 48 months or were
seen at London Health Sciences Centre, a second regional NBS
center in London, Ontario. The control group included a
random sample of mothers of infants who screened negative
for all conditions, identified through Newborn Screening
Ontario. Most questionnaire data were collected from mothers
of screen-positive and -negative infants when they were 4-6
weeks of age. For mothers of infants identified retrospec-
tively, data were collected when infants were 6-48 months of
age. Mothers of infants facing extenuating perinatal stressors
(eg, infants deceased, in clinical distress, premature, mul-
tiples), those undergoing adoption proceedings, or with sig-
nificant language barriers were excluded, as well as those cases
requiring additional testing for technical reasons. The Re-
search Ethics Boards at The Hospital for Sick Children, The
Children’s Hospital of Eastern Ontario, Western University, and
The University of Toronto approved the study.
Data Collection
We collected psychosocial data through a cross-sectional, self-
administered questionnaire and semistructured open-ended
interviews with mothers. We report quantitative psychoso-
cial data from mothers of infants with inconclusive, true posi-
tive, and screen-negative results and qualitative interview data
from parents of infants with inconclusive diagnoses follow-
ing confirmatory testing.
Survey of Mothers
The survey package included a team-developed, self-
administered questionnaire gauging knowledge of CF, under-
standing of screening result, attitudes towards NBS, psychosocial
measures, and demographic questions and relevant study in-
formation, consent, forms, and a small financial incentive (a
$2 coffee shop coupon). The questionnaire was pretested with
new parents recruited from the Greater Toronto Area (N = 15)
through an online mothers’ group (to reflect mothers of
“healthy” children) and the CF community (to reflect mothers
of children with CF).
The team-developed questionnaire was adapted from ex-
isting validated instruments used in infant/NBS research.21-25,27-29
The core questionnaire was consistent across groups; content
specific to the screen-positive experience was excluded from
the version distributed to the screen-negative control group.
We present overall scores on 3 well-established and validated
psychosocial response measures:27 (1) the state subscale of the
State Trait Anxiety Inventory28 as a measure of parental anxiety,
(2) a modified version of the Parental Perceptions of Uncer-
tainty in Illness Scale29 as a measure of perceived uncertainty
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related to childhood illness, and (3) the Child Vulnerability
Scale24 as a measure of maternal perception of infant
vulnerability.
Questionnaire data were manually entered into IBM SPSS
Statistics, version 18 (IBM Corp, Armonk, New York). Double
data entry was performed for the uncertain and true positive
samples. Two cases were removed from the quantitative analy-
sis because their inconclusive results were verified to be true
negative at the time of survey completion (ie, by 6 months of
age; Figure available at www.jpeds.com). We quantified the
overall pattern of responses using proportions for discrete vari-
ables and medians with IQRs for continuous variables. We per-
formed nonparametric tests of significance given non-normal
distributions of the data.
Interviews with Parents
Interview respondents were recruited from those who had in-
conclusive results, had completed a questionnaire, and indi-
cated willingness to participate in an interview, or expressed
a preference to complete an interview rather than a question-
naire. Because qualitative interviews were retrospective in nature,
the 2 “resolved” cases that were removed from the quantita-
tive analysis remained in the qualitative sample (Figure). When
both parents were present at the time of the interview, both
were invited to participate. We conducted telephone inter-
views when face-to-face interviews were not feasible. One
member of the study team conducted all interviews.
The interview guide queried parents’ experiences receiv-
ing the screen-positive notification, their preparation for and
experience during the sweat test appointment, their under-
standing of the screening and test results, and their lived
experience thereafter as related to parenting and medical follow-
up. We captured parents’ experience over time in 2 ways. First,
all interviews were retrospective in nature, enabling parents to
reflect back on their experience. Second, parents were invited
to participate in a second interview 1 year following their first
interview. Interview data were taped, transcribed, and coded
by the project team. We used interpretive description, a low
inference analytic strategy that draws on the tenets of natu-
ralistic inquiry and emphasizes a close engagement with the
respondent’s own representation of events, to analyze tran-
script data.30 Using a thematic approach, we applied and modi-
fied pre-existing codes (from the interview guide) as sensitizing
concepts and allowed new themes to emerge from the data.
Codes were generated by the authors and transcripts were coded
independently by an additional author. Through an iterative
process, codes were refined and inconsistencies were resolved
by discussion.
Results
Eligible mothers of 39 infants who received inconclusive di-
agnoses were invited to participate; 19 completed the survey
(response rate [RR] 48.7%) and 2 were excluded from the
survey analysis because their inconclusive results were veri-
fied to be true negative at the time of survey completion. Fifteen
surveys were completed by mothers of true-positive infants
(RR 62.5%), and 410 surveys were completed by mothers of
screen-negative infants (RR 47.2%).27 Mothers of infants with
inconclusive diagnoses lived in less urban locations and were
less well educated than both comparison groups (P < .05) and
had greater household income than the screen-negative control
group (P = .01) (Table I).
Psychosocial Results
Anxiety and vulnerability scores among mothers of infants with
inconclusive diagnoses were not different from mothers of true
positive infants or mothers of screen-negative controls. Mothers
of infants with inconclusive diagnoses reported greater per-
ceived uncertainty scores than mothers of true positive infants
(P = .002) and screen-negative infants (P < .001) (Table II).
Itemized Parental Perceptions of Uncertainty in Illness Scale
responses indicate that compared with mothers of true posi-
tive and screen-negative infants, more mothers of infants with
inconclusive results were unsure about whether their infant had
a health condition (P = .002). Compared with mothers of
screen-negative infants, mothers of infants with inconclusive
results had “unanswered questions about their baby’s health”
(P = .001) and heard “many meanings” from doctors about their
baby’s health (P < .001) (Table III).
Qualitative Interview Sample
Parents of 18 children were interviewed (parents of 13 chil-
dren were interviewed once, and parents of 5 children were
interviewed twice, with the second interview 1 year follow-
ing the first interview). For 2 of these children, inconclusive
results were resolved as true negatives. For 16 children, mothers
were interviewed; for 2 children, both mother and father were
interviewed (n = 20 parents). Children ranged from 4 months
to 4 years old.
Qualitative Findings
Parents of infants with inconclusive results experienced relief
that their child did not have “full-blown” CF and appreciated
the value the knowledge might have for the child or other family
members in the future. They struggled, however, to make sense
of what was perceived as an uncomfortable diagnostic cat-
egory. The experience of uncertainty involved 3 additional di-
mensions: unsettled meaning, heightened sense of medical
vulnerability, and mixed feelings about surveillance (Table IV).
Unsettled Meaning. Parents described being unsettled about
an inconclusive diagnosis, particularly in the face of a child
who “looks perfect.” They reported being uncertain—and there-
fore unsettled—about the nature of the health complications
that their child might experience, as well as the timing of po-
tential CF-related manifestations. Parents reported receiving
different messages from providers about what inconclusive
results meant; some providers characterized inconclusive results
as a potential form of disease (eg, “atypical CF”) where symp-
toms could emerge anytime,“in six months or ten years or fifty
years. . .” (participant ID 106), whereas others avoided using
a disease label.
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Heightened Sense of Medical Vulnerability. Diagnostic un-
certainty led some parents to perceive their child as medi-
cally vulnerable, leading to active symptom seeking. Parents
described,“licking their babies for saltiness (ID 147)”; they also
affixed CF-related meaning to unusual but normal newborn
behavior (eg, spitting up). Others sought symptoms less
actively but emphasized feeling a heightened sense of
awareness or sensitivity towards ultimately benign coughs and
colds.
In some cases, health-related vulnerability had a cascade
of effects: parents reported delayed infant bonding or
altered parenting/decision-making styles. With time,
however, most described growing confidence in their
child’s health and a much-decreased sense of medical
vulnerability.
Mixed Feelings About Surveillance. Families faced deci-
sions related to continuing assessment through the clinic. At
the time of the qualitative interviews, all families (except the
2 for whom results resolved) remained engaged in this follow-
up protocol. Participants expressed belief that being engaged
in ongoing monitoring contributed to needed knowledge for
themselves and for science and enabled access to medical experts
that would not otherwise be available; however, many also
viewed the process as emotionally draining for themselves and/
or their otherwise-healthy child. For some, gaining confi-
dence in their child’s health over time reduced the perceived
burden of ongoing surveillance. Others were less favorable
towards ongoing surveillance as their children got older and
feared psychological vulnerability related to potential label-
ing effects.








n (%) n (%) P value† (vs uncertain) n (%) P value† (vs uncertain)
Age, y
≤25 0 (0.0) 1 (6.7) .075 27 (6.7) .127
26-30 2 (11.8) 2 (13.3) 110 (27.1)
31-35 6 (35.3) 10 (66.7) 160 (39.4)
36+ 9 (52.9) 2 (13.3) 109 (26.8)
City size
100 000+ 7 (41.2) 12 (80.0) .036 330 (80.5) .001
<100 000 10 (58.8) 3 (20.0) 80 (19.5)
First child
Yes 10 (58.8) 9 (60.0) 1.000 127 (40.3) .139
No 7 (41.2) 6 (40.0) 188 (59.7)
Marital status
Married or common law 16 (94.1) 14 (86.7) 1.000 380 (92.7) 1.000
Single 1 (5.9) 1 (6.7) 30 (7.3)
Education, highest level completed
High school or less 0 (0.0) 1 (7.1) .043 57 (14.0) .047
College or CEGEP 11 (64.7) 3 (21.4) 107 (26.2)
Undergraduate 2 (11.8) 6 (42.9) 112 (27.5)
Graduate or professional 4 (23.5) 4 (28.6) 132 (32.4)
Income
<$80 000 2 (12.5) 2 (14.3) 1.000 180 (45.2) .010
$80 000+ 14 (87.5) 12 (85.7) 218 (54.8)
CEGEP, collège d'enseignement général et professionnel.




Table II. Mothers’ psychosocial response to newborn screening results
Psychosocial response
measures
Inconclusive (n = 17)* True positive (n = 15)† Screen negative (n = 410)‡
Median (IQR) Median (IQR) P value§ (vs inconclusive) Median (IQR) P value§ (vs inconclusive)
STAI¶ 33.50 (18.00) 38.00 (14.00) .092 31.00 (12.00) .927
CVS** 7.00 (8.00) 7.50 (8.25) .681 5.00 (7.00) .082
PPUS†† 12.00 (5.00) 8.00 (3.25) .002 8.00 (3.00) <.001
CVS, Child Vulnerability Scale; PPUS, Parental Perceptions of Uncertainty Scale; STAI, State Trait Anxiety Inventory.
*STAI and PPUS n = 16 due to missing data.
†PPUS and CVS n = 14 due to missing data.
‡STAI, n = 379; CVS, n = 396; PPUS, n = 404 due to missing data.
§Mann-Whitney U test.
¶STAI: state subscale used; scores range from 20 to 80; mean (working women) is 34.79 (SD = 9.22); mean (14 weeks' postpartum women) 30.43.28
**CVS: scores range from 0 to 24. In a clinical population, scores ≥10 indicate elevated perceptions of vulnerability.24
††PPUS: scores range from 0 to 20; greater scores indicate greater perception of uncertainty.29
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Table III. Parental perceptions of uncertainty (itemized responses to PPUS)
Questions
Inconclusive (n = 17)* True positive (n = 15)† Screen negative (n = 410)‡





1. I have no idea whether or not my baby has a health problem
Strongly agree/agree 7 (43.8) 0 .002 43 (10.6) .002
Undecided 2 (12.5) 0 53 (13.1)
Strongly disagree/disagree 7 (43.8) 14 (100.0) 308 (76.2)
2. I have a lot of questions without answers about my baby's health
Strongly agree/agree 7 (41.2) 1 (6.7) .083 42 (10.4) .001
Undecided 2 (11.8) 2 (13.3) 33 (8.1)
Strongly disagree/disagree 8 (47.1) 12 (80.0) 330 (81.5)
3. Doctors say things about my baby that could have many meanings
Strongly agree/agree 6 (37.5) 3 (20.0) .545 30 (7.4) <.001
Undecided 3 (18.8) 2 (13.3) 31 (7.7)
Strongly disagree/disagree 7 (43.8) 10 (66.7) 344 (84.9)
4. I know what my baby's chances are of getting sick
Strongly agree/agree 7 (41.2) 4 (26.7) .045 165 (40.7) .344
Undecided 3 (17.6) 9 (60.0) 129 (31.9)
Strongly disagree/disagree 7 (41.2) 2 (13.3) 111 (27.4)
*Items 1 and 3 n = 16 due to missing data.
†Item 1 n = 14 due to missing data.




Table IV. Qualitative themes and illustrative quotes
Relief and value placed on knowledge unto itself, for most
“I was relieved and I was interested in how it all worked so I wanted to know all the details. . . it's important, you know, it probably will have little effect on her life, so
I'm not that concerned but we wanted to have all the information for her. . .” (ID 292)
“I really thought about [her getting sick] all day and night for a month. . . . And you can't get that month back. [. . .] It's still taking a while to let that go. I feel like I
missed out on just enjoying that month. [. . .] the most upsetting part about this is I feel like I didn't do the same things that I would have done with her. . .” (ID 055)
Unsettled meaning
“. . .it's one of those weird genes. . .he doesn't have classic CF but we can't say that he doesn't have CF at all; it was very wishy-washy which was unsettling. . . I
walked away feeling confused. . .” (ID 033)
“at least we knew it was not the classic form. . . they said. . .he may have some organ problems later in life that are associated, like, stomach or lung problems. . .”
(ID 296)
“one doctor said, it looks like she has atypical cystic fibrosis and here's what you might expect in the future, like pneumonia, sinus infections. . .. Another doctor said,
I don't want you to use atypical cystic fibrosis in regards to your daughter. At this point she's a completely healthy child. . . she has the makings of someone who
may have atypical symptoms in the future, but at this point, there's nothing wrong with her. . .” (ID 190)
Heightened sense of medical vulnerability
“he's got this cough. . .it drives me insane, I hate it, they say CF carriers are a little bit more mucousy. . . and that it's a normal cough, nothing to be alarmed; but
when he gets mucousy it's horrible,. . . you're constantly thinking like, OK, well, is the CF active now?” (ID 172)
“I stayed up every night from when she was born. I was sleeping in her room with my hand on her back to make sure that I could feel her breathing. . .. It was. . .
probably until she was about 2 that I wasn't worried about it on a daily basis. . . and even now. . . she's treated differently. . . Even though she's not sick, she's got
a diagnosis. . . We looked at going up to [small town] but we didn't because of the air quality—I wasn't sure how that would affect her. . .” (ID 106)
“I think, as hard as it was when she was little, we were still grateful to know and we still are now, like it's, we don't think about it and worry about it often, at all
anymore, so it's not, it's not a big issue for our family right now. . ..” (ID 404)
Mixed feelings about surveillance
“. . . I would rather know than not know. . .because she's being monitored and we don't, I feel like we don't have to worry about it as much as we would if, you know,
she was 15 and all of a sudden, like oh, well she's had all these years of not getting enough of vitamins or has fluid in her lungs, or whatever, mucus, so no, I'm
very glad that we know about it, even though it kind of sucks.” (ID 404)
“We mostly go just for the research aspect. . .And that way whatever they can find out about her to help other kids would be great. . .But I also get to know that her
scans come back clear, her chest x-rays, her ultrasounds. And it gives a little bit peace of mind for myself. . . So I think I do it more for the reassurance for
myself. . .” (ID 168)
“Once I had a really strong sense that he was in the clear I did not want anybody else to have to go through that uncertainty. If there's anything I can do to contribute
to them just knowing a little bit more then I want to do it.” (ID 176)
“. . .it's very draining as a parent. . . At our last visit the doctor said, ‘well her stomach's a little distended, let's check her intestines.’ And I'm like, this has to stop. At
some point this, looking for every single thing, has to stop. If we're talking about severe respiratory infections, ok, then I'll look at it. But, if her stomach's a little
distended, maybe she ate a little more?” (ID 106)
“I'm pro research. . .. but I don't want him to think something's wrong with him. . . Kids with classic CF or who are symptomatic need to see doctors. . . If he's a
healthy boy, I'm not opposed to research. . . but at what cost? It was not an issue in his first 18 months but now he's becoming much, much, much more aware.
You know, we came home from the hospital last month and he said, ‘am I sick?’ He said, ‘I sick? I sick?” (ID 033)
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Discussion
We explored the experience of, and psychosocial response to,
diagnostic uncertainty following CF NBS. Encouragingly, in-
conclusive results were not associated with measurable anxiety
or vulnerability among mothers of infants who received these
results; however, our data do signal various manifestations of
health-related uncertainty and subtle distress. Qualitatively,
parents reflected relief about the absence of frank disease but
uncertainty about what an inconclusive diagnosis means, what
to expect medically, and how to manage their child’s needs in
the face of this uncertainty. Despite these challenges, parents
felt supported by and endorsed regular monitoring in the early
days, valued the ongoing relationships with experts, and sup-
ported the goals of research. As parents gained confidence in
their child’s health over time, some came to question ongoing
monitoring because of its potential negative impact on their
child’s identity, whereas others continued to feel supported by
it. These findings extend those of other studies,20-22 which report
subtle forms of emotional disturbance among parents of infants
with inconclusive diagnoses.
Our findings contribute to ongoing debates about the im-
plications of diagnostic uncertainty for NBS practices and poli-
cies related to generating inconclusive results and optimizing
support for families who receive them. New evidence indi-
cates that some of these infants ultimately have CF; some would
argue that this evidence justifies their early identification and
initiation of treatment, whereas others, like Massie and
Clements,14 argue that, “missing these infants on NBS is an ac-
ceptable limitation of the program that is by nature a screen-
ing program.” In addition, recent work suggests that the general
public understands the concept of unclear screening diagno-
ses and views this outcome unfavorably.31 Although we did not
detect a clear quantitative signal of psychosocial harm, a clear
qualitative signal of distress suggests that continued expan-
sion of NBS, in turn generating more complex-to-interpret
results, may not be a harmless trend. Combined with related
work, our findings underscore the importance of using patient-
reported outcomes that reflect on both the benefits and po-
tential harms of inconclusive results in decisions related to
suitable screening targets and optimal screening algorithms.31
Evidence on the family experience of receiving inconclu-
sive results and pursuing surveillance also can inform the de-
velopment of evidence-based postscreening care and
surveillance protocols. Our findings suggest that NBS provid-
ers, primary care providers, and specialists implicated in
short- and longer-term postscreening care (ie, notification, con-
firmatory testing, ongoing surveillance) may be called on to
assess and attend to parents’ psychosocial response to this con-
sequence of screening. Because the newborn period is a time
of critical parent-child bonding and identity shaping for both
parents and their infants,20,32 equipping the postscreening care
system with capacity to respond with clear messaging, evidence-
based protocols, and educational/psychosocial support re-
sources is warranted. Because our findings related to diagnostic
uncertainty pertain to a less urban and less well-educated parent
group, we infer that these particular demographic categories
may be more vulnerable to subtle distress and require addi-
tional support. Finally, our findings add to the debate about
whether and how prospective parents should be informed of
this possible outcome in advance of NBS. Although many have
emphasized the potential value of fulsome pre-NBS education,33
NBS typically is not accompanied by formal systems of pretest
education and consent through which parents can be ap-
prised of this possible outcome.33-35 This current structural
reality places further pressure on optimizing both the
screening algorithm as well as the postscreening care
environment.
We acknowledge the limitations of this relatively small, pri-
marily single-site sample, and variable age ranges and time of
assessment since the diagnostic uncertainty was declared. The
salience of the qualitative findings related to perceived vul-
nerability combined with the subtle quantitative trend towards
increased vulnerability among those with inconclusive results
highlights the possibility that this study was underpowered to
detect meaningful differences on this dimension. Our study
sample also may not be fully representative of the popula-
tion of infants and families affected by diagnostic uncer-
tainty. Nonetheless, this work adds to the knowledge base
regarding the psychosocial impact of medical surveillance trig-
gered by diagnostic uncertainty from CF NBS. It is novel in
its mixed methods approach and contributes to our under-
standing of the complex nature of NBS-generated uncer-
tainty. Further evaluation, and support for these families, is
warranted. ■
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19 mothers completed surveys
2 excluded 
(inconclusive results 
resolved as true 
negative at time
survey completed)
Parents of 18 infants agreed to interview
13 parents agreed 
to 1 interview
5 parents agreed to 2 
interviews
N = 23 
interviews
N = 17 
surveys
Figure. Sample of parents with infants with inconclusive results.
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